Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis DOI Creative Commons
Satoru Taguchi, Taketo Kawai,

Y. Ambe

et al.

International Journal of Urology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Abstract Background While the occurrence of immune‐related adverse events has been recognized as a prognostic marker in patients receiving immune checkpoint inhibitors, significance treatment‐related (trAEs) undergoing antibody–drug conjugates such enfortumab vedotin (EV) is controversial. Methods We reviewed 106 with advanced urothelial carcinoma who were treated EV therapy at 10 institutions between 2021 and 2023. Associations clinical parameters overall survival progression‐free assessed using Cox proportional hazards model. For assessment trAEs, landmark analysis was conducted to minimize immortal time bias. Results Of patients, 55 (51.9%) experienced disease progression 44 (41.5%) died during follow‐up period. Any grade ≥3 trAEs occurred 94 (88.7%) respectively. Common included skin disorders (74.5%), gastrointestinal (62.3%), fatigue (50.0%), peripheral neuropathy (36.8%), hematological (37.7%). One patient interstitial pneumonia (grade 5). According 88 survived for 2 months or more, significantly associated longer survival. Furthermore, when classified into “physical trAEs” “laboratory disorders, former while latter shorter Conclusions Physical, but not laboratory, are favorable outcomes carcinoma. Both managing utilizing them markers key points use EV.

Language: Английский

Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis DOI Creative Commons
Satoru Taguchi, Taketo Kawai,

Y. Ambe

et al.

International Journal of Urology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Abstract Background While the occurrence of immune‐related adverse events has been recognized as a prognostic marker in patients receiving immune checkpoint inhibitors, significance treatment‐related (trAEs) undergoing antibody–drug conjugates such enfortumab vedotin (EV) is controversial. Methods We reviewed 106 with advanced urothelial carcinoma who were treated EV therapy at 10 institutions between 2021 and 2023. Associations clinical parameters overall survival progression‐free assessed using Cox proportional hazards model. For assessment trAEs, landmark analysis was conducted to minimize immortal time bias. Results Of patients, 55 (51.9%) experienced disease progression 44 (41.5%) died during follow‐up period. Any grade ≥3 trAEs occurred 94 (88.7%) respectively. Common included skin disorders (74.5%), gastrointestinal (62.3%), fatigue (50.0%), peripheral neuropathy (36.8%), hematological (37.7%). One patient interstitial pneumonia (grade 5). According 88 survived for 2 months or more, significantly associated longer survival. Furthermore, when classified into “physical trAEs” “laboratory disorders, former while latter shorter Conclusions Physical, but not laboratory, are favorable outcomes carcinoma. Both managing utilizing them markers key points use EV.

Language: Английский

Citations

1